Our results indicate that NTHL1 p.Q90* heterozygous carriers do not have an increased risk for breast cancer and that the variant is unlikely to be a significant contributor to breast cancer risk at the population level, a notion that is particularly important for genetic counseling. Here, NTHL1 is linked to breast cancer.